Literature DB >> 22907938

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

L Daelman1, A Maitrot, A Maarouf, M P Chaunu, C Papeix, A Tourbah.   

Abstract

We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation. FTY was started 3.5 months after a two-year NZB treatment. Fifteen days later, she suffered partial repetitive seizures followed by a tonicoclonic seizure. This was associated with attention difficulties and an increased asthenia. Brain MRI follow-up disclosed large demyelinating active lesions in favour of disease reactivation. This case suggests that FTY introduction may occur less than three months after NZB withdrawal.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907938     DOI: 10.1177/1352458512458009

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  16 in total

Review 1.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

2.  Immune cell trafficking from the brain maintains CNS immune tolerance.

Authors:  Mohammad G Mohammad; Vicky W W Tsai; Marc J Ruitenberg; Masoud Hassanpour; Hui Li; Prue H Hart; Samuel N Breit; Paul E Sawchenko; David A Brown
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.

Authors:  Maria Sepúlveda; Sara Llufriu; Yolanda Blanco; Nuria Solà-Valls; Delon La Puma; Joan Berenguer; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

4.  Switching therapies in multiple sclerosis.

Authors:  Patricia K Coyle
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

5.  Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Authors:  Joachim Havla; Björn Tackenberg; Kerstin Hellwig; Ingrid Meinl; Markus Krumbholz; Florian Seitz; Christian Eienbröker; Ralf Gold; Reinhard Hohlfeld; Ingo Kleiter; Tania Kümpfel
Journal:  J Neurol       Date:  2012-12-25       Impact factor: 4.849

6.  Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alessandra Lugaresi; Maria di Ioia; Daniela Travaglini; Erika Pietrolongo; Eugenio Pucci; Marco Onofrj
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

Review 7.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

Review 8.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

Review 9.  Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Authors:  Robert Hoepner; Simon Faissner; Anke Salmen; Ralf Gold; Andrew Chan
Journal:  J Cent Nerv Syst Dis       Date:  2014-04-28

Review 10.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.